Ørnbjerg, L. M., Østergaard, M., Jensen, T., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Hetland, M. L., ... OPERA Study Group (2017). Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology, 36(4), 781-789. https://doi.org/10.1007/s10067-016-3489-1
Ørnbjerg, LM, Østergaard, M, Jensen, T, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Lottenburger, T, Ammitzbøll, CG, Jørgensen, A, Krintel, SB, Raun, J, Hetland, ML, Slot, O, Nielsen, LK, Skjødt, H, Majgaard, O, Lorenzen, T, Horn, HC, Kowalski, M, Johansen, IL, Pedersen, PM, Manilo, N, Bliddal, H & OPERA Study Group 2017, 'Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial', Clinical Rheumatology, vol. 36, no. 4, pp. 781-789. https://doi.org/10.1007/s10067-016-3489-1
Ørnbjerg LM, Østergaard M, Jensen T, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P et al. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology. 2017 Apr 1;36(4):781-789. doi: 10.1007/s10067-016-3489-1
@article{27d3a442bfde49599d4d2d55f06d7b35,
title = "Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial",
abstract = "This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/− adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0–6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/−radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) −1.9 (−3.3; −0.26 mg/cm2) in the MTX + placebo group and −1.8 (−3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = −0.086 (95% confidence interval = −0.15; −0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92–1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.",
keywords = "Journal Article",
author = "{\O}rnbjerg, {Lykke Midtb{\o}ll} and Mikkel {\O}stergaard and Tonny Jensen and K H{\o}rslev-Petersen and Kristian Stengaard-Pedersen and Peter Junker and T Ellingsen and P Ahlquist and H Lindegaard and A Linauskas and A Schlemmer and Dam, {Mette Yde} and I Hansen and T Lottenburger and Ammitzb{\o}ll, {C G} and A. J{\o}rgensen and Krintel, {Sophine Boysen} and Johnny Raun and Hetland, {Merete Lund} and Ole Slot and Nielsen, {Lars Kj{\ae}r} and Henrik Skj{\o}dt and Ole Majgaard and Tove Lorenzen and Horn, {Hans Christian} and Marcin Kowalski and Johansen, {Inger Lauge} and Pedersen, {Peter Mosborg} and Natalia Manilo and Henning Bliddal and {OPERA Study Group}",
year = "2017",
month = apr,
day = "1",
doi = "10.1007/s10067-016-3489-1",
language = "English",
volume = "36",
pages = "781--789",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer",
number = "4",
}
TY - JOUR
T1 - Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial
AU - Ørnbjerg, Lykke Midtbøll
AU - Østergaard, Mikkel
AU - Jensen, Tonny
AU - Hørslev-Petersen, K
AU - Stengaard-Pedersen, Kristian
AU - Junker, Peter
AU - Ellingsen, T
AU - Ahlquist, P
AU - Lindegaard, H
AU - Linauskas, A
AU - Schlemmer, A
AU - Dam, Mette Yde
AU - Hansen, I
AU - Lottenburger, T
AU - Ammitzbøll, C G
AU - Jørgensen, A.
AU - Krintel, Sophine Boysen
AU - Raun, Johnny
AU - Hetland, Merete Lund
AU - Slot, Ole
AU - Nielsen, Lars Kjær
AU - Skjødt, Henrik
AU - Majgaard, Ole
AU - Lorenzen, Tove
AU - Horn, Hans Christian
AU - Kowalski, Marcin
AU - Johansen, Inger Lauge
AU - Pedersen, Peter Mosborg
AU - Manilo, Natalia
AU - Bliddal, Henning
AU - OPERA Study Group
PY - 2017/4/1
Y1 - 2017/4/1
N2 - This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/− adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0–6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/−radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) −1.9 (−3.3; −0.26 mg/cm2) in the MTX + placebo group and −1.8 (−3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = −0.086 (95% confidence interval = −0.15; −0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92–1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.
AB - This study aims to investigate 1-year hand bone loss (HBL1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/− adalimumab and to determine if HBL6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL6months (0–6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/−radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p < 0.10 were included in multivariable models. In 70 patients with available HBL1-year data, HBL1-year was median (interquartile range (IQR)) −1.9 (−3.3; −0.26 mg/cm2) in the MTX + placebo group and −1.8 (−3.6; 0.06) mg/cm2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL6months data and 2-year radiographic data, HBL6months was independently associated with ∆TSS after 2 years (β = −0.086 (95% confidence interval = −0.15; −0.025) TSS unit/mg/cm2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92–1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL1-year, irrespective of adalimumab; HBL6months was independently associated with ∆TSS after 2 years.
KW - Journal Article
U2 - 10.1007/s10067-016-3489-1
DO - 10.1007/s10067-016-3489-1
M3 - Journal article
C2 - 27921185
SN - 0770-3198
VL - 36
SP - 781
EP - 789
JO - Clinical Rheumatology
JF - Clinical Rheumatology
IS - 4
ER -
